Britain and America have hammered out a significant bilateral deal that will preserve zero tariffs on British drug shipments being sold in the American market.
The Terms of the Pact
As part of the deal, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This move guarantees that tariffs on these crucial exports will remain at zero for a duration of three years.
This deal is in response to recent warnings to hike tariffs on patented drug products, with figures floated reaching 100%.
"This arrangement with the UK strengthens the international landscape for new treatments and brings long-overdue balance to U.S.–U.K. drug exports," a release noted.
Trade Impact
Medicines represent one of the the United Kingdom's largest exports to the America, which is clearly the largest destination for leading companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months prior to the third quarter, the UK sold pharmaceutical products valued at £11.1bn to the US. This amount accounted for a significant portion of all goods exports in that timeframe.
"This agreement secures employment, boosts investment and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," a minister remarked.
Specific UK Commitments
The agreement involves several notable changes from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a target to raise total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must return to the NHS to prevent overspending will be capped at 15%. Last year, rebates were more than 20%.
Broader Context
The deal comes amid a ongoing row between the drug companies and the UK government over spending levels and NHS adoption.
The disagreement were heightened by assertions that US customers were charged several times more for the equivalent treatments than patients in the other developed nations.
In recent months, several significant drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
One official publicly accepted that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.
